Quick answer: Total testosterone levels in American men have declined approximately 1% per year since the 1980s — meaning a 60-year-old man today has testosterone levels 20–25% lower than a 60-year-old man in 1988, independent of aging, according to the Travison 2007 Massachusetts Male Aging Study analysis. This secular decline parallels rising rates of obesity, insulin resistance, endocrine-disrupting chemical exposure, and sleep deprivation — all modifiable factors that functional medicine directly targets. Men’s hormonal health encompasses far more than testosterone replacement: it includes HPG axis optimization, thyroid and adrenal co-factors, sexual health, prostate biology, bone and muscle preservation, and the metabolic conditions that accelerate hormonal decline.
Testosterone Physiology: The HPG Axis and What Disrupts It
The hypothalamic-pituitary-gonadal (HPG) axis governs testosterone production through a precisely regulated hormonal cascade. The hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulsatile fashion every 90–120 minutes; this stimulates pituitary LH and FSH release; LH acts on Leydig cells in the testes to stimulate testosterone synthesis; testosterone provides negative feedback to both hypothalamus and pituitary, completing the regulatory loop. The pulsatile nature of GnRH is essential — continuous GnRH stimulation (as achieved pharmacologically with GnRH agonists like leuprolide) paradoxically suppresses LH through receptor downregulation, the mechanism behind chemical castration for prostate cancer.
The most impactful modifiable disruptors of the HPG axis in contemporary men include: insulin resistance and adiposity (adipose aromatase converts testosterone to estradiol, and adipokines directly suppress GnRH pulsatility); sleep deprivation (testosterone is primarily secreted during slow-wave sleep — Leproult and Van Cauter 2011, JAMA found that sleeping 5 hours for one week reduced testosterone by 10–15%); chronic psychological stress (sustained HPA axis activation suppresses GnRH through CRH- and cortisol-mediated inhibition of the HPG axis); endocrine-disrupting chemicals (phthalates, BPA, dioxins — all documented Leydig cell toxins and androgen receptor antagonists); and chronic opioid use (opioids directly suppress GnRH pulsatility and LH release, producing opioid-induced hypogonadism in 50–90% of long-term users).
SHBG (sex hormone-binding globulin) is the transport protein that binds approximately 44% of circulating testosterone in a high-affinity, biologically inactive complex, with 50% loosely albumin-bound (bioavailable) and only 2–3% free. As SHBG rises — driven by aging, thyroid hormone, liver synthetic function, caloric restriction, and estrogen — the biologically available testosterone fraction falls even when total testosterone remains unchanged. Elevated SHBG is among the most common causes of symptomatic hypogonadism with “normal” total testosterone. Functional assessment requires free testosterone (calculated or equilibrium dialysis method) and SHBG measurement alongside total testosterone. Insulin resistance lowers SHBG — which is why obese insulin-resistant men often have lower SHBG and apparently normal free testosterone despite genuinely suppressed HPG axis output.
Diagnosing Hypogonadism: Beyond the Reference Range
Standard laboratory reference ranges for total testosterone (typically 300–1,000 ng/dL or 270–1,070 ng/dL depending on the assay) were largely derived from populations including elderly, obese, and sick men — systematically biasing the lower bound downward. Bhasin and colleagues’ landmark research (2001, NEJM) establishing the testosterone dose-response for muscle mass and strength found that clinical benefits of testosterone optimization are maximal in men with total testosterone above 700–800 ng/dL — not merely above the laboratory minimum of 300 ng/dL. The symptom burden of low-normal testosterone (300–450 ng/dL) in an otherwise healthy 45-year-old is clinically identical to frank hypogonadism, yet most practitioners would not treat based on laboratory values alone.
Validated symptom assessment tools — the Aging Males’ Symptoms (AMS) scale and the Androgen Deficiency in the Aging Male (ADAM) questionnaire — quantify the clinical burden of androgen deficiency independently of laboratory values. Symptoms of low testosterone include: reduced libido and sexual function, decreased morning erections, reduced physical energy and exercise capacity, loss of muscle mass and strength despite maintained training, increased body fat particularly visceral, depression and reduced motivation, cognitive slowing, reduced bone density, and increased cardiovascular risk. When symptom burden is high and testosterone is low-normal (300–500 ng/dL), functional medicine prioritizes upstream optimization before pharmacological TRT.
Pre-TRT laboratory evaluation should include: total and free testosterone (morning sample, 8–10am, two separate measurements on different days); LH and FSH (distinguishes primary from secondary hypogonadism — low LH with low testosterone indicates hypothalamic-pituitary dysfunction); SHBG; estradiol (E2) with sensitive liquid chromatography-mass spectrometry assay (not immunoassay); prolactin (elevated prolactin suppresses GnRH); complete blood count and hematocrit (TRT increases erythropoiesis — baseline essential); PSA (prostate cancer screening mandatory before TRT); and thyroid function (thyroid hormone directly modulates SHBG and testosterone metabolism).
Natural Testosterone Optimization: The Evidence Base
Before considering TRT, comprehensive lifestyle and nutritional optimization can meaningfully raise testosterone in men who are not genuinely hypogonadal from primary testicular failure. The effect sizes are modest individually but clinically significant in combination and without the suppression of endogenous production and fertility associated with exogenous testosterone.
Resistance training is the most consistently documented natural testosterone stimulant. Kraemer and colleagues (1990) and subsequent meta-analyses confirm that heavy compound resistance exercises (squats, deadlifts, bench press) acutely raise testosterone by 20–40% post-workout, and that sustained resistance training programs increase resting testosterone by 15–25% in untrained or detrained men. The testosterone response is greatest with high-volume, multi-joint exercises at 80%+ 1-RM with minimal rest intervals. Importantly, the androgenic response to exercise requires adequate dietary fat intake — low-fat diets (below 20% of calories) are documented to suppress testosterone, with a 2000 analysis by Hamalainen and colleagues showing testosterone 13% lower in men on very low-fat diets.
Zinc is an essential cofactor for testosterone synthesis — Leydig cells have the highest zinc concentration of any cell type, and zinc is required for the enzymatic conversion of androstenedione to testosterone. A 1996 study by Prasad and colleagues demonstrated that 6 months of zinc supplementation (25mg/day) in mildly zinc-deficient elderly men raised testosterone from a mean of 8.3 to 16.0 nmol/L — a near-doubling. Zinc deficiency is common in athletes (losses via sweat), vegetarians (poor bioavailability from phytate-rich foods), and men with gut dysbiosis impairing absorption. Serum zinc below 70 μg/dL or red blood cell zinc below 120 μg/dL (more sensitive) warrants supplementation at 15–30mg/day of highly bioavailable zinc bisglycinate or zinc picolinate.
Vitamin D deficiency — present in 40–70% of men depending on latitude and sun exposure — independently predicts low testosterone. Pilz and colleagues (2011, Hormone and Metabolic Research) conducted the first RCT of vitamin D supplementation (3,332 IU/day for 12 months) in 165 overweight men, finding that testosterone rose significantly in the vitamin D group (from 10.7 to 13.4 nmol/L, a 25.2% increase) versus no change in controls. The mechanism involves vitamin D response elements in the promoter region of the testosterone synthesis gene CYP11A1 — vitamin D directly drives the transcription of the enzymes that produce testosterone in Leydig cells. Target serum 25-OH vitamin D for testosterone optimization: 50–80 ng/mL.
Prostate Health: BPH, PSA, and Cancer Prevention
Benign prostatic hyperplasia (BPH) affects approximately 50% of men by age 60 and 90% by age 85, producing lower urinary tract symptoms (LUTS) including urinary frequency, urgency, nocturia, and reduced flow that substantially impair quality of life. BPH pathophysiology involves DHT (dihydrotestosterone) — the more potent 5α-reduced form of testosterone — acting on androgen receptors in the periurethral zone of the prostate to drive cellular proliferation. Paradoxically, absolute testosterone levels do not predict BPH severity; the ratio of DHT to testosterone (reflecting 5α-reductase activity) and DHT-independent inflammatory processes are more important.
Saw palmetto (Serenoa repens) extract has been the most studied natural intervention for BPH, with a 2012 Cochrane review by Tacklind and colleagues analyzing 32 RCTs with 5,666 participants. At standard doses (320mg/day of liposterolic extract), saw palmetto produced modest but consistent improvements in LUTS scores and urinary flow rates versus placebo, with a markedly superior side-effect profile to pharmaceutical 5α-reductase inhibitors (finasteride, dutasteride) that cause sexual dysfunction in 15–20% of users. However, a landmark 2011 NEJM trial by Barry and colleagues found that escalating saw palmetto doses did not improve outcomes over placebo in a rigorous double-blind design — suggesting the benefit may be dose- and extract quality-dependent.
Lycopene — the carotenoid pigment in tomatoes, watermelon, and grapefruit — is the dietary compound with the strongest epidemiological association with prostate cancer prevention. A 2002 meta-analysis by Giovannucci and colleagues (Journal of the National Cancer Institute) found that 11 of 12 studies showed an inverse association between lycopene intake and prostate cancer risk, with the highest intake quartile showing approximately 21% lower risk. The mechanisms involve lycopene’s upregulation of gap junction intercellular communication (which suppresses uncontrolled cell proliferation), inhibition of IGF-1 signaling, and antioxidant effects on DNA methylation. Cooking tomatoes in olive oil (lycopene in pizza sauce, tomato paste) dramatically increases bioavailability compared to raw tomatoes — an unusually practical evidence-based recommendation.
PSA (prostate-specific antigen) interpretation requires functional medicine nuance beyond the binary positive/negative framing of conventional screening. PSA velocity (rate of change over time) is more clinically significant than single values — a PSA rising from 1.0 to 2.5 ng/mL over 12 months warrants more concern than a stable PSA of 3.8 ng/mL. PSA density (PSA divided by prostate volume on MRI) adjusts for prostate size — a PSA of 5.0 in a 100cc prostate is less concerning than PSA of 5.0 in a 20cc prostate. Free-to-total PSA ratio below 10–15% suggests higher cancer probability among men with PSA in the 4–10 ng/mL “gray zone.” Advanced PSA derivatives (PHI — Prostate Health Index — and 4Kscore) outperform standard PSA for predicting clinically significant prostate cancer.
Erectile Dysfunction as a Cardiovascular Risk Signal
Erectile dysfunction (ED) affects approximately 30 million American men and is the first clinical manifestation of systemic endothelial dysfunction in a substantial proportion of cases. The Princeton Consensus — the most cited expert framework for ED and cardiovascular risk — recognizes ED as an independent cardiovascular risk marker, with multiple studies demonstrating that ED precedes cardiovascular events by 2–5 years in a significant proportion of men. A 2011 meta-analysis by Inman and colleagues found that ED was associated with approximately 48% increased risk of cardiovascular disease over follow-up periods of 2–10 years.
The pathophysiology is unified by endothelial NOS (eNOS) dysfunction. Penile erection requires NO-mediated relaxation of the corpus cavernosum smooth muscle — the same eNOS-dependent pathway that drives coronary vasodilation and peripheral arterial compliance. The penile arteries (1–2mm diameter) develop endothelial dysfunction and atherosclerotic disease earlier than the coronary arteries (3–4mm diameter) due to their smaller size and greater flow-demand ratio — making ED a harbinger of systemic cardiovascular disease. A comprehensive ED evaluation in a 50-year-old man should therefore include full cardiovascular risk stratification: ApoB, Lp(a), hs-CRP, TMAO, coronary calcium scoring, and metabolic assessment including HOMA-IR.
Dietary nitrates — found abundantly in beetroot, arugula, spinach, and celery — are reduced to NO via the salivary nitrate-nitrite pathway, independent of eNOS. This oral NO pathway is particularly relevant for men with ED because it bypasses the eNOS dysfunction driving the condition. A 2017 study by Baradaran and colleagues found that beetroot juice supplementation improved erectile function scores, and multiple studies show correlation between dietary nitrate intake and penile blood flow. Combined with pelvic floor physical therapy (which addresses venous insufficiency and pelvic floor muscle dysfunction contributing to ED), dietary nitrate supplementation represents a mechanistically rational intervention distinct from PDE-5 inhibitors.
Bone Health in Men: The Underappreciated Epidemic
Osteoporosis in men is dramatically underdiagnosed — only 5% of men receive screening compared to 50–60% of women — despite the fact that one in four men over 50 will experience an osteoporotic fracture, and men have substantially higher mortality after hip fracture (up to 37% 1-year mortality) compared to women. Testosterone, estradiol, and IGF-1 are all critical for maintaining bone mineral density in men. Estradiol — derived primarily from peripheral aromatization of testosterone in men — appears to be more important than testosterone for bone density maintenance; men with low estradiol despite normal testosterone have accelerated bone loss.
DEXA (dual-energy X-ray absorptiometry) scanning should be standard in men over 50 with any of the following risk factors: testosterone deficiency, glucocorticoid use, smoking, excessive alcohol, inflammatory bowel disease, chronic malabsorption, low BMI, or family history of hip fracture. Functional assessment adds bone turnover markers (CTX for bone resorption, P1NP for bone formation) to identify the specific phase of bone loss and monitor treatment response. Vitamin K2 (specifically MK-7, 100–200mcg/day) activates osteocalcin to bind calcium to the bone matrix while simultaneously preventing arterial calcification — a dual benefit particularly relevant for men with cardiovascular risk alongside bone loss. Strontium ranelate, while not available in the US, has demonstrated equivalent fracture reduction to bisphosphonates with a potentially superior cardiovascular risk profile in European trials.
Frequently Asked Questions
What is a normal testosterone level for men? Laboratory reference ranges (typically 300–1,000 ng/dL) include a floor derived from elderly and ill populations that does not represent optimal function. Research by Bhasin and others suggests clinical benefits of testosterone maximize above 700–800 ng/dL. Functional medicine considers both laboratory values and symptom burden — a man with total testosterone of 380 ng/dL and significant symptoms of hypogonadism warrants investigation and intervention, not reassurance that his value is “normal.” Free testosterone and SHBG are equally important.
Does testosterone therapy cause prostate cancer? The “testosterone-prostate cancer” hypothesis — that testosterone drives prostate cancer growth — originated with Charles Huggins’ 1941 observations that castration regressed metastatic prostate cancer. However, decades of subsequent research failed to show that men with higher testosterone have higher prostate cancer rates. Morgentaler and Traish (2009, European Urology) proposed the “saturation model” — prostate androgen receptors saturate at relatively low testosterone concentrations (~200 ng/dL), above which additional testosterone does not increase cancer risk. Large systematic reviews of TRT confirm no significant increase in prostate cancer incidence or PSA in hypogonadal men on therapy versus controls.
What supplements can increase testosterone naturally? Evidence-supported options: zinc (15–30mg/day of bisglycinate) — significantly raises testosterone in zinc-deficient men; vitamin D3 (targeting 50–80 ng/mL) — 25% testosterone increase in RCT in vitamin D-deficient men; ashwagandha KSM-66 — Wankhede 2015 RCT found 17% testosterone increase with 300mg twice daily in resistance-trained men; DHEA (25–50mg/day) — raises testosterone precursor pool, particularly relevant above age 50. Adequate dietary fat intake (35–40% of calories) and sleep (7–9 hours) are non-negotiable foundations. No supplement overcomes a broken foundation.
What causes erectile dysfunction in younger men? ED in men under 40 is increasingly common and is most often multifactorial: endothelial dysfunction from insulin resistance and poor cardiovascular fitness; low testosterone or high SHBG; elevated estradiol (particularly in overweight men with high aromatase activity); psychological contributors (performance anxiety, depression, relationship factors); pornography-induced sexual conditioning; sleep apnea causing nocturnal testosterone suppression; and endocrine-disrupting chemical exposure. A comprehensive evaluation including full metabolic panel, hormonal assessment, cardiovascular risk, and sleep study is warranted — not empiric PDE-5 inhibitor prescription without investigation.
How is BPH treated naturally? Evidence-supported natural BPH interventions: saw palmetto liposterolic extract (160mg twice daily) for modest LUTS improvement; pumpkin seed extract (400–500mg/day) — Vahlensieck 2015 RCT found significant improvement in IPSS score; dietary modification reducing refined carbohydrates and inflammatory fats (insulin resistance drives prostate inflammation); regular aerobic exercise (reduces sympathetic tone driving detrusor overactivity); maintaining adequate zinc status for 5α-reductase and androgen receptor modulation; and pelvic floor physical therapy for functional components of LUTS.
Men’s hormonal health is a lifelong investment, not a problem that appears at 50 and requires pharmaceutical management. The hormonal decline that most men experience is substantially driven by modifiable lifestyle factors — insulin resistance, sleep deprivation, endocrine-disrupting chemical exposure, sedentary behavior, and nutritional deficiency — that functional medicine directly addresses. Whether you are seeking to optimize testosterone naturally, evaluate the need for TRT, address erectile dysfunction at its root, or build a prostate cancer prevention strategy, The Private Practice offers the comprehensive evaluation your health deserves. Call (810) 206-1402 to schedule.